Lavezzari G - Search Results

1

What evidence do we need for biomarker qualification?

Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L, Brumfield M, Chin WW, Hoffmann S, Kelloff G, Lavezzari G, Ranganathan R, Sauer JM, Sistare FD, Zabka T, Wholley D. Leptak C, et al. Among authors: lavezzari g. Sci Transl Med. 2017 Nov 22;9(417):eaal4599. doi: 10.1126/scitranslmed.aal4599. Sci Transl Med. 2017. PMID: 29167393 Review.

2

Industry perspectives on biomarker qualification.

Lavezzari G, Womack AW. Lavezzari G, et al. Clin Pharmacol Ther. 2016 Feb;99(2):208-13. doi: 10.1002/cpt.264. Epub 2015 Oct 22. Clin Pharmacol Ther. 2016. PMID: 26378777 Free PMC article. Review.

3

Advancing Value Assessment in the United States: A Multistakeholder Perspective.

Sorenson C, Lavezzari G, Daniel G, Burkholder R, Boutin M, Pezalla E, Sanders G, McClellan M. Sorenson C, et al. Among authors: lavezzari g. Value Health. 2017 Feb;20(2):299-307. doi: 10.1016/j.jval.2016.11.030. Value Health. 2017. PMID: 28237214 Free article.

4

International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions.

Reed SD, Lavezzari G. Reed SD, et al. Among authors: lavezzari g. Value Health. 2016 Sep-Oct;19(6):727-729. doi: 10.1016/j.jval.2016.06.004. Value Health. 2016. PMID: 27712697 Free article. No abstract available.

5

Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.

Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, Parsons KK, Marshak AG, Garavaglia S, Dechairo BM. Winner JG, et al. Among authors: lavezzari g. Curr Med Res Opin. 2015;31(9):1633-43. doi: 10.1185/03007995.2015.1063483. Epub 2015 Jul 23. Curr Med Res Opin. 2015. PMID: 26086890

6

Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays.

Lavezzari G, Lackner MR. Lavezzari G, et al. Methods Mol Biol. 2012;795:203-15. doi: 10.1007/978-1-61779-337-0_14. Methods Mol Biol. 2012. PMID: 21960225

7

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.

Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Mazzocca A, et al. Among authors: lavezzari g. Hepatology. 2009 Oct;50(4):1140-51. doi: 10.1002/hep.23118. Hepatology. 2009. PMID: 19711426

8

Corequirement of PICK1 binding and PKC phosphorylation for stable surface expression of the metabotropic glutamate receptor mGluR7.

Suh YH, Pelkey KA, Lavezzari G, Roche PA, Huganir RL, McBain CJ, Roche KW. Suh YH, et al. Among authors: lavezzari g. Neuron. 2008 Jun 12;58(5):736-48. doi: 10.1016/j.neuron.2008.03.028. Neuron. 2008. PMID: 18549785 Free PMC article.

9

mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.

Pelkey KA, Yuan X, Lavezzari G, Roche KW, McBain CJ. Pelkey KA, et al. Among authors: lavezzari g. Neuropharmacology. 2007 Jan;52(1):108-17. doi: 10.1016/j.neuropharm.2006.07.020. Epub 2006 Aug 17. Neuropharmacology. 2007. PMID: 16914173

10

Constitutive endocytosis of the metabotropic glutamate receptor mGluR7 is clathrin-independent.

Lavezzari G, Roche KW. Lavezzari G, et al. Neuropharmacology. 2007 Jan;52(1):100-7. doi: 10.1016/j.neuropharm.2006.07.011. Epub 2006 Aug 7. Neuropharmacology. 2007. PMID: 16890965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters